MDxHealth SA has released its unaudited financial results for the first quarter of 2025. The company reported revenues of $24.292 million, marking an increase from $19.834 million in the same period of 2024. The gross profit rose to $15.504 million from $12.063 million year-over-year. However, the company also reported a net loss of $9.209 million for the quarter, which widened from the $8.511 million net loss recorded in the first quarter of the previous year. The operating loss for the quarter improved to $4.588 million, compared to a loss of $6.604 million in the same period last year. General and administrative expenses increased slightly to $5.842 million from $5.359 million, while selling and marketing expenses decreased to $9.821 million from $10.028 million. Research and development expenses also saw a rise to $2.499 million from $2.164 million. From a cash flow perspective, MDxHealth reported a net cash outflow from operating activities of $2.632 million, which is a reduction from the $5.515 million outflow in the corresponding period of the previous year. In terms of investing activities, the company had a net cash inflow of $13,000, as opposed to a net cash outflow of $618,000 in the first quarter of 2024. The company also highlighted significant financing activities, reporting proceeds from loan obligations, net of fees, amounting to $24.250 million. MDxHealth continues to focus on its strategic priorities to drive growth and enhance its financial performance.